Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT7ILZ1)

• DTT Name: SLAM family member 7 SLAMF7 (CS1) DTT Info
• Gene Name: SLAMF7

Molecule-Related Drug & Molecule List

1 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Elotuzumab	DMEYHG9	Multiple myeloma	2A83	Approved	[1]

6 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PVX-410	DM6DK9A	Multiple myeloma	2A83	Phase 2	[1]
ABBV-838	DMZM0T8	Multiple myeloma	2A83	Phase 1	[2]
BCMA-CS1 cCAR	DMEPHMR	Multiple myeloma	2A83	Phase 1	[3]
CS1-CAR T Therapy	DMU8OCN	Plasma cell myeloma	2A83.1	Phase 1	[4]
MB-104	DMRP4BM	Multiple myeloma	2A83	Phase 1	[5]
UCARTCS1	DM2Y4D7	Multiple myeloma	2A83	Phase 1	[6]

References

• [1] Market watch: Upcoming catalysts in Q2 2015. Nat Rev Drug Discov. 2015 Apr;14(4):228.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT04156269) BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT03710421) CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
• [5] Clinical pipeline report, company report or official report of Mustang Bio.
• [6] ClinicalTrials.gov (NCT04142619) Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01). U.S. National Institutes of Health.